


Serial No. 10/694,845

PAGE 2  
Docket No. 51630AUSC1AMENDMENTS TO THE CLAIMS

The below listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-11 (Cancelled).

Claim 12 (Amended). A compound of formula I,



wherein

$R^1$  and  $R^2$  are, independently of one another, hydrogen,  $C_{1-6}$  alkyl,  $OR^7$ ,  $NR^7R^8$ , CN, acyl,  $CO_2R^9$ ,  $CONR^7R^8$  or  $CSNR^7R^8$ ,

$R^3$  is a saturated or unsaturated  $C_{1-5}$  alkylene radical, which is optionally substituted in 1 to 4 places with  $OR^7$ ,  $NR^{11}R^{12}$  or  $C_{1-4}$  alkyl and which are is optionally bridged with a methano, ethano or propano group,

$R^4$  is  $C_{1-4}$  alkyl substituted with  $NR^{14}R^{15}$ ,

$R^5$  is hydrogen, halogen,  $OR^7$ ,  $C_{1-4}$  alkyl,  $CF_3$ , or  $OCF_3$ ,

or,  $R^4$  and  $R^5$  optionally together with 2 adjacent carbon atoms form a  $C_3$ - $C_4$  alkylene moiety optionally substituted in one or two places with  $NR^{14}R^{15}$ ,

~~$R^5$  and  $R^6$  is are, independently of one another, Hydrogen, halogen,  $OR^7$ ,  $C_{1-4}$  alkyl,  $CF_3$ , or  $OCF_3$ ,~~

$R^7$ ,  $R^{18}$  and  $R^{19}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,

$R^8$ ,  $R^{11}$  and  $R^{12}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,  $COR^{10}$ ,  $CO_2R^{10}$ ,  $CONR^{18}R^{19}$  or  $CSNR^{18}R^{19}$ ,

Serial No. 10/694,845

PAGE 3  
Docket No. 51630AUSC1 $R^9, R^{10}$ 

and  $R^{20}$  are, independently of one another,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,

$R^{14}$  and  $R^{15}$  are, independently of one another, Hydrogen,  $CO_2R^{20}$  or  $C_{1-6}$  alkyl, which optionally is substituted with halogen, hydroxy,  $C_{1-4}$  alkoxy, nitro, amino,  $C_{1-6}$  alkyl, trifluoromethyl, carboxyl, cyano, carboxamido,  $C_{3-7}$  cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl,  $C_{6-10}$  aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkyl,  $CF_3$ ,  $NO_2$ ,  $NH_2$ ,  $N(C_{1-4} \text{ alkyl})_2$  or carboxyl, ~~or~~ and

n is 0, 1 or 2,

or a tautomeric or isomeric form of or a salt of a compound of formula I.


Claim 13 (Previously Presented): A compound according to claim 12, in which  $R^3$  is a  $C_{1-5}$  alkylene radical, which is optionally bridged with a methano, ethano or propano group.

Claim 14 (Previously Presented): A compound according to claim 12, in which  $R^1$  and  $R^2$  is hydrogen.

Claim 15 (Amended): A pharmaceutical composition comprising an effective amount of a compound according to claims 12, and a pharmaceutically acceptable vehicle or adjuvant.

Claims 16-18 (Cancelled).

Claim 19 (Amended): A compound of formula I,



wherein

$R^1$  and  $R^2$  are, each independently, hydrogen or  $C_{1-6}$  alkyl,

Serial No. 10/694,845

PAGE 4  
Docket No. 51630AUSC1

$R^3$  is a saturated or unsaturated  $C_{1-5}$  alkylene radical, which is optionally substituted in 1 to 4 places with  $OR^7$ ,  $NR^{11}R^{12}$  or  $C_{1-4}$  alkyl and which are is optionally bridged with a methano, ethano or propano group,

$R^4$  is  $C_{1-4}$  alkyl, substituted with  $NR^{14}R^{15}$ ,

$R^5$  is hydrogen, halogen,  $OR^7$ ,  $C_{1-4}$  alkyl,  $CF_3$ , or  $OCF_3$ ,

or,  $R^4$  and  $R^5$  optionally together with 2 adjacent carbon atoms form a  $C_3$ -  $C_4$  alkylene moiety optionally substituted in one or two places with  $NR^{14}R^{15}$ ,

$R^5$  and  $R^6$  is are, independently of one another, Hydrogen, halogen,  $OR^7$ ,  $C_{1-4}$  alkyl,  $CF_3$ , or  $OCF_3$ ,

$R^7$ ,  $R^{18}$   
and  $R^{19}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,

$R^8$ ,  $R^{11}$   
and  $R^{12}$  are, independently of one another, Hydrogen,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,  $COR^{10}$ ,  $CO_2R^{10}$ ,  $CONR^{18}R^{19}$  or  $CSNR^{18}R^{19}$ ,

$R^9$ ,  $R^{10}$   
and  $R^{20}$  are, independently of one another,  $C_{1-6}$  alkyl or  $C_{6-10}$  aryl, which optionally is substituted with halogen or  $C_{1-4}$  alkyl,

$R^{14}$  and  $R^{15}$  are, independently of one another, Hydrogen,  $CO_2R^{20}$  or  $C_{1-6}$  alkyl, which optionally is substituted with halogen, hydroxy,  $C_{1-4}$  alkoxy, nitro, amino,  $C_{1-6}$  alkyl, trifluoromethyl, carboxyl, cyano, carboxamido,  $C_{3-7}$  cycloalkyl, indanyl, 1,2,3,4-tetrahydronaphthyl,  $C_{6-10}$  aryl, wherein the aryl radical is optionally substituted with halogen, hydroxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkyl,  $CF_3$ ,  $NO_2$ ,  $NH_2$ ,  $N(C_{1-4} \text{ alkyl})_2$  or carboxyl, ~~or~~ and

$n$  is 0, 1 or 2,

or a tautomeric or isomeric form of or a salt of a compound of formula I.

Claim 20 (Previously Presented): A compound according to claim 19, wherein  $R^3$  is a  $C_{1-5}$  alkylene radical, which is optionally bridged with a methano, ethano or propane group.

Claim 21 (Cancelled).

Serial No. 10/694,845

PAGE 5  
Docket No. 51630AUSC1

Claim 22 (New): A compound according to claim 12, which is selected from the group consisting of:

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-(3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-[1-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-[1-(3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-8-chloro-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-8-chloro-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline, and

4-amino-7-(3-chlorobenzylamino)methyl-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline dihydrochloride.

Claim 23 (New): A pharmaceutical composition according to claim 15, in which R<sup>3</sup> is a C<sub>1-5</sub> alkylene radical, which is optionally bridged with a methano, ethano or propano group.

Claim 24 (New): A pharmaceutical composition according to claim 15, in which R<sup>1</sup> and R<sup>2</sup> is hydrogen.

Claim 25 (New): A pharmaceutical composition according to claim 15, wherein the compound is selected from the group consisting of:

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

Serial No. 10/694,845

PAGE 6  
Docket No. 51630AUSC1

4-amino-7-(3-chlorobenzylamino)methyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-[1-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-7-[1-(3-chlorobenzylamino)propyl]-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)ethyl-8-chloro-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline,

4-amino-8-chloro-7-(3-chlorobenzylamino)ethyl-2,3,3a,9b-tetrahydro-1H-cyclopenta[c]quinoline dihydrochloride,

4-amino-7-(N-tert-butyloxycarbonyl-3-chlorobenzylamino)-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline, and

4-amino-7-(3-chlorobenzylamino)methyl-1,2,3,3a,7,8,9,10b-octahydro-dicyclopenta[c,g]quinoline dihydrochloride.